Elbe Kliniken Stade-Buxtehude

Itching in Atopic Dermatitis: Patient-and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany (2023) Weisshaar E, Bentz P, Apfelbacher C, Haufe E, Heinrich L, Heratizadeh A, Abraham S, et al. Journal article Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry (2022) Haist M, Stege H, Lang BM, Tsochataridou A, Salzmann M, Mohr P, Schadendorf D, et al. Journal article Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Meier F, Weichenthal M, Grimmel-Mann I, Gutzmer R, Utikal JS, et al. Conference contribution Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG (2022) Franklin C, Mohr P, Bluhm L, Grimmelmann I, Gutzmer R, Meier F, Garzarolli M, et al. Conference contribution Real-world clinical outcomes of pembrolizumab for advanced melanoma in the German ADOREG skin cancer registry (2022) Mohr P, Scherrer E, Alar V, Assaf C, Beissert S, Berking C, Eigentler T, et al. Conference contribution Predictors of long-term survival of stage IV melanoma patients: a multicenter DeCOG study on 539 patients from the prospective skin cancer registry ADOREG (2022) Placke JM, Mohr P, Bluhm L, Kahler K, Weichenthal M, Meier F, Garzarolli M, et al. Conference contribution Therapy Management of the first Recurrence after adjuvant Therapy in Stage III: multicenter real-world Data (2022) Lodde G, Forschner A, Hassel JC, Wulfken LM, Meier F, Mohr P, Kaehler K, et al. Conference contribution Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study (2022) Berking C, Livingstone E, Weichenthal M, Leiter-Stoeppke U, Remy J, Eigentler T, Mohr P, et al. Conference contribution Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany (2022) Mohr P, Scherrer E, Assaf C, Bender M, Berking C, Chandwani S, Eigentler T, et al. Journal article Effectiveness, safety and drug survival of dupilumab in patients with moderate to severe atopic dermatitis: an interim analysis of the TREATgermany registry (2022) Stoelzl D, Boraczynski N, Heratizadeh A, Haufe E, Harder I, Abraham S, Heinrich L, et al. Conference contribution